Hormonal
Subcutaneous semaglutide (2.4 mg once weekly) produces significant weight loss (mean 14.9% body weight reduction in STEP 1) and improves cardiometabolic markers (waist circumference, blood pressure, HbA1c, lipids) compared to placebo in adults with obesity.
For adults with obesity, subcutaneous semaglutide (2.4 mg weekly) is a highly effective treatment that reduces body weight by approximately 15% and improves cardiovascular risk factors. It is well-tolerated, though gastrointestinal side effects like nausea are common; these can be mitigated by slow dose escalation and dietary adjustments. It is superior to other weight loss medications in clinical trials.
Participants treated with semaglutide achieved a reduction in waist circumference, improvements in blood pressure parameters, HbA1c levels, total cholesterol, LDL cholesterol, triglycerides, and CRP protein, and increased HDL cholesterol levels.
Why this rating
Based on multiple Phase 3 randomized controlled trials (STEP 1, 2, 3, SUSTAIN, PIONEER) and meta-analyses cited.
Source
Semaglutide for the treatment of obesity
Rafał Oleszczuk et al. · Journal of Education Health and Sport · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →